A Safety and Efficacy Study of Intra-tumoural Diffusing Alpha Radiation Emitters for the Treatment of Vulva Cancer

Vulva Cancer Clinical Trial

— DaRT-V  

Official title:

A Safety and Efficacy Study of Intra-tumoural Diffusing Alpha Radiation Emitters (DaRT) for the Treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04761146
• Other study ID #: DaRT-V
• Status: Recruiting
• Phase: N/A
• Start date: February 28, 2023
• Est. completion date: January 1, 2026

Study information

• Verified date: May 2023
• Source: Cambridge University Hospitals NHS Foundation Trust
• Contact: Urology, Haematology and Medical Devices Team Clinical Trials Un
• Phone: 01223216083
• Email: cctuc[@]addenbrookes.nhs.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An investigation to investigate the use of diffusing alpha-emitters radiation therapy (DaRT) for the treatment of new and recurrent squamous cell carcinoma of the vulva.

Description:

Squamous cell carcinoma of the vulva is a rare cancer accounting for less than 1% of female cancers. The disease predominantly affects women over the age of 65 although the incidence in younger women is rising, a finding that has been attributed to the effect of increasing human papillomavirus (HPV) infection . The standard treatment for the primary tumour is surgical excision with the aim of achieving a 1 cm clear margin on histopathology. This requires the surgeon to remove 1.5-2 cm of surrounding normal tissue to allow for shrinkage after tissue fixation. Depending on the size and location of the tumour, the surgical procedure could vary from a wide local excision to a radical vulvectomy, including excision of adjacent structures such as the clitoris, lower urethra or anus, and/or reconstructive surgery. Wound infection and breakdown are common short-term complications of radical vulva surgery. Long term consequences include functional, cosmetic, psychological and psychosexual sequelae, which can have a significant negative impact on quality of life. Recurrence rates for vulva squamous cell carcinomas range from 15% to 33%. Local recurrence in the vulva is the most common site of relapse (70%) with the groin nodes affected in 24%, pelvic nodes in 16% and distant metastases in 19%. The treatment of choice for local recurrence is surgical excision and 5-year survival rates of up to 45% have been reported. However, patients can develop multiple recurrences over a period of time and the feasibility of surgery becomes increasingly more limited as more and more tissue is removed. Brachytherapy is a form of radiotherapy where radiation sources are placed directly in contact with or into (interstitial) cancerous tissue. The radiation emitted has a short range in tissue and the brachytherapy dose distribution conforms tightly to the location of the sources with minimal dose to the surrounding healthy tissues. Alpha Tau Medical Ltd. proposes a novel treatment for malignant tumours using intra-tumoural alpha radiation, which is delivered using the Alpha DaRT Device (Alpha DaRT applicator + Alpha DaRT seeds). The technique, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), combines the advantages of conventional interstitial brachytherapy with the destructive power of alpha particles.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: January 1, 2026
• Est. primary completion date: September 1, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Newly diagnosed or recurrent (local) vulva cancer with or without distant metastases
• Histopathological confirmation of squamous cell carcinoma
• Macroscopic tumour in situ (i.e. tumour not excised)
• Age 18 years and over
• ECOG performance status 0-2
• Life expectancy more than 6 months
• Willing and able to give written informed consent to participate
• Measurable target according to RECIST v1.1
• Tumour size = 7 centimetres in the longest diameter
• Target is technically amenable for full coverage by the DaRT seeds

Exclusion Criteria:

• Non-squamous histology
• Concomitant illnesses which may increase risk of radiation toxicity e.g. autoimmune diseases, vasculitis, etc.
• Concomitant immunosuppressive and/or long-term corticosteroid treatment
• Involvement in other studies that may affect evaluation of response or toxicity of DaRT in the past 30 days or 5 half-lives of the investigational product, whichever is longer
• Pregnancy or breastfeeding
• Women of child-bearing potential unwilling to use adequate contraception for the duration of the study and 6 months after completion (further details in CIP section 13)
• Nodal recurrence without local recurrence
• Previous diagnosis of other malignancy < 3 years of enrolment (excluding non-melanomatous skin cancer)
• No concurrent chemotherapy
• Patients who have received prior chemotherapy or targeted therapy require a 1-month washout before DaRT insertion
• Requirement to start chemotherapy within 6 weeks of DaRT insertion

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Vulva Cancer
• Vulva Cancer, Recurrent
• Vulvar Neoplasms
• Vulvar Squamous Cell Carcinoma

Intervention

Radiation:
• DaRT Diffusing Alpha-emitters Radiation Therapy
DaRT is a brachytherapy treatment comprising stainless-steel 316LVM wires coated with radium-224 (Alpha DaRT seeds). The radioactive seeds are inserted directly into the tumour on the perineum and will be removed after 14 days.

Locations

Country	Name	City	State
United Kingdom	Cambridge University Hospitals NHSFT	Cambridge	Cambridgehire

Sponsors (2)

Lead Sponsor	Collaborator
CCTU- Cancer Theme	Alpha Tau Medical LTD.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assess the feasibility of DaRT by the safety of DaRT for the treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva	Measuring the feasibility of using the device by the treatment-related adverse events in the follow-up period (graded 1 'not significant' to 5 'death' with Common Terminology Criteria for Adverse Events v5.0)	6 months
Secondary	Assess the efficacy of DaRT for the treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva	Tumour response at 4 weeks (Day 28) after DaRT insertion as assessed by Response Evaluation Criteria in Solid Tumours (RECIST, complete response to progressive disease) criteria	Day 28 (4 weeks)
Secondary	To evaluate the effect DaRT on the immunological response	Histological evidence of necrosis in pathological lymph nodes if removed.	4-6 weeks
Secondary	Assess the efficacy of DaRT for the treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva	Local control rate at 3-month and 6-month follow-up visits	6 months
Secondary	Assess the efficacy of DaRT for the treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva	Patient numerical rating scale (NRS) pain score, '0' representing "no pain" to '10' representing "extreme pain"	6 months
Secondary	Assess the efficacy of DaRT for the treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva	Patient mental state using the European Organisation for Research and Treatment of Cancer Quality of Life questionnaire. Scored 1-4 from 'Not at All' to 'Very Much'	6 months
Secondary	Assess the efficacy of DaRT for the treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva	Percentage of necrotic tissue if residual tumour is removed surgically	4-6 weeks
Secondary	Assess the efficacy of DaRT for the treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva	Patients physical state using the European Organisation for Research and Treatment of Cancer Quality of Life questionnaire. Scored 1-4 from 'Not at All' to 'Very Much'	6 months